Clinical trial
Exploratory Phosphoproteomic Study to Discover DYRK1A-Dependent Blood Biomarkers in TriSomy 21 Carriers
NCT06279208 is registered in ClinicalTrials.gov with Perha Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Exploratory Phosphoproteomic Study to Discover DYRK1A-Dependent Blood Biomarkers in TriSomy 21 Carriers
- Lead sponsor
- Perha Pharmaceuticals
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 18, 2024
- Completion date
- April 16, 2025
- Enrollment
- 60 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.